Volastra Therapeutics, Inc.

Laboratorios Del Dr. Esteve S.a.

Esteve Pharmaceuticals, S.a.

Piotr Nieczypor

Sarah Bettigole

Leon Van Berkom

Michael Su

Carmen Almansa-Rosales

José-Luis Díaz-Fernández

Rutger Folmer

Prashanna Vijayachandran

Gydo Van Der Heijden

José Luis Diaz-Fernandez

The present disclosure relates generally to inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disclosure relates to triazolopyrimidine and imidazolopyrimidine inhibitors of ENPP1 and methods of their use for treating disease mediated by ENPP1.

Heterocyclic inhibitors of ENPP1

The present disclosure relates generally to inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disclosure relates to sulfoximine-based inhibitors of ENPP1 and methods of their use for treating disease mediated by ENPP1.

Imino sulfanone inhibitors of ENPP1

The present invention relates to new fused imidazolyl derivatives having a high affinity for sigma receptors, especially sigma-1 receptors, as well as to the process for the preparation thereof, to compositions comprising them, and to their use as medicaments.

Fused imidazolyl derivatives, their preparation and use as medicaments

Growing community of inventors

Nijmegen, Netherlands

Piotr Nieczypor